JYMed
Shenzhen JYMed Technology Co.,Ltd is a high-tech enterprise engaged in research and development, manufacturing and commercialization of peptides based products including active pharmaceutical ingredient peptides, cosmetic peptides, and custom peptides as well as new peptide drug development. JYMed is one of the largest peptide manufacturers in China.
JYMed
Join JYMed Peptide at Pharmaconex 2025！
JYMed Peptide is pleased to invite you to Pharmaconex 2025, taking place from September 1–3, 2025, at the Egypt International Exhibition Center (EIEC) in Cairo. Covering an exhibition area of 12,000+ square meters, the event will host 350+ exhibitors and is expected to attract 8,000+ professional visitors.
With 45% of North Africa’s APIs dependent on imports and a 2024 supply gap of 230,000 tons, along with an equipment renewal demand exceeding USD 1.5 billion, the region offers substantial market opportunities. Now in its 11th edition, Pharmaconex has grown into the largest and most influential pharmaceutical industry platform in Africa and the Middle East.
4 months ago | [YT] | 0
View 0 replies
JYMed
Join JYMed Peptide at CPhI Korea 2025！
JYMed Peptide is delighted to invite you to CPhI Korea 2025, taking place from August 26–28, 2025, at the COEX Convention & Exhibition Center in Seoul. Spanning 15,000 square meters, the event is expected to host more than 450 exhibitors and welcome over 10,000 professional visitors.
In 2024, South Korea’s pharmaceutical exports reached USD 9.5 billion, ranking 8th worldwide. As the gateway of choice for international companies seeking to enter the Korean and broader Asia-Pacific markets, CPhI Korea offers unparalleled opportunities for networking, partnerships, and market expansion.
4 months ago | [YT] | 0
View 0 replies
JYMed
Join JYMed at CPHI South East Asia 2025！
6 months ago | [YT] | 0
View 0 replies
JYMed
Meet JYMed at Interphex Week Tokyo 2025
6 months ago | [YT] | 0
View 0 replies
JYMed
Join JYMed at CPHI China 2025！
6 months ago | [YT] | 0
View 0 replies
JYMed
JYMed’s Peptide Production Base in Hubei Passes Second Consecutive FDA Inspection
Hubei JXBio Pharmaceutical Co., Ltd., JYMed’s dedicated peptide production site, successfully completed another on-site inspection by the U.S. Food and Drug Administration (FDA) from March 10-14. The inspection, part of a Drug Quality Assurance audit, evaluated key systems including quality, production, equipment and facilities, lab controls, and material management. APIs reviewed included Liraglutide, Semaglutide, Tirzepatide, and Oxytocin.
6 months ago | [YT] | 0
View 0 replies
JYMed
JYMed Peptide at “Expo Farma 2025”
9 months ago | [YT] | 0
View 0 replies